February 10, 2025 · Form 4 insider transaction
RA CAPITAL MANAGEMENT, L.P. sold 451,580 shares of Sionna Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.; RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.; Held directly by the Nexus Fund.